207 related articles for article (PubMed ID: 25445496)
1. Potential limitations of IL-2 administration for the treatment of experimental acute graft-versus-host disease.
Pérol L; Martin GH; Maury S; Cohen JL; Piaggio E
Immunol Lett; 2014 Dec; 162(2 Pt B):173-84. PubMed ID: 25445496
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
Shin HJ; Baker J; Leveson-Gower DB; Smith AT; Sega EI; Negrin RS
Blood; 2011 Aug; 118(8):2342-50. PubMed ID: 21734238
[TBL] [Abstract][Full Text] [Related]
3. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
Giorgini A; Noble A
J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
[TBL] [Abstract][Full Text] [Related]
4. Effect of rapamycin and interleukin-2 on regulatory CD4+CD25+Foxp3+ T cells in mice after allogenic corneal transplantation.
Wang X; Wang W; Xu J; Le Q
Transplant Proc; 2013 Mar; 45(2):528-37. PubMed ID: 23267787
[TBL] [Abstract][Full Text] [Related]
5. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells.
Coenen JJ; Koenen HJ; van Rijssen E; Kasran A; Boon L; Hilbrands LB; Joosten I
Bone Marrow Transplant; 2007 May; 39(9):537-45. PubMed ID: 17351648
[TBL] [Abstract][Full Text] [Related]
7. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
[TBL] [Abstract][Full Text] [Related]
8. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice.
Mutis T; van Rijn RS; Simonetti ER; Aarts-Riemens T; Emmelot ME; van Bloois L; Martens A; Verdonck LF; Ebeling SB
Clin Cancer Res; 2006 Sep; 12(18):5520-5. PubMed ID: 17000688
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
[TBL] [Abstract][Full Text] [Related]
10. Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease.
Sugiyama H; Maeda Y; Nishimori H; Yamasuji Y; Matsuoka K; Fujii N; Kondo E; Shinagawa K; Tanaka T; Takeuchi K; Teshima T; Tanimoto M
Biol Blood Marrow Transplant; 2014 Feb; 20(2):183-91. PubMed ID: 24333142
[TBL] [Abstract][Full Text] [Related]
11. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
Sykes M; Abraham VS; Harty MW; Pearson DA
J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
[TBL] [Abstract][Full Text] [Related]
12. Generation of Human Alloantigen-Specific Regulatory T Cells Under Good Manufacturing Practice-Compliant Conditions for Cell Therapy.
Cheraï M; Hamel Y; Baillou C; Touil S; Guillot-Delost M; Charlotte F; Kossir L; Simonin G; Maury S; Cohen JL; Lemoine FM
Cell Transplant; 2015; 24(12):2527-40. PubMed ID: 25198125
[TBL] [Abstract][Full Text] [Related]
13. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
[TBL] [Abstract][Full Text] [Related]
14. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo.
Zhang P; Tey SK; Koyama M; Kuns RD; Olver SD; Lineburg KE; Lor M; Teal BE; Raffelt NC; Raju J; Leveque L; Markey KA; Varelias A; Clouston AD; Lane SW; MacDonald KP; Hill GR
J Immunol; 2013 Nov; 191(10):5291-303. PubMed ID: 24123683
[TBL] [Abstract][Full Text] [Related]
15. Generation of highly effective and stable murine alloreactive Treg cells by combined anti-CD4 mAb, TGF-β, and RA treatment.
Schliesser U; Chopra M; Beilhack A; Appelt C; Vogel S; Schumann J; Panov I; Vogt K; Schlickeiser S; Olek S; Wood K; Brandt C; Volk HD; Sawitzki B
Eur J Immunol; 2013 Dec; 43(12):3291-305. PubMed ID: 23946112
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.
Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M
Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312
[TBL] [Abstract][Full Text] [Related]
17. Host CD25+CD4+Foxp3+ regulatory T cells primed by anti-CD137 mAbs inhibit graft-versus-host disease.
Kim J; Kim W; Kim HJ; Park S; Kim HA; Jung D; Choi HJ; Park SJ; Mittler RS; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2012 Jan; 18(1):44-54. PubMed ID: 21958951
[TBL] [Abstract][Full Text] [Related]
18. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
[TBL] [Abstract][Full Text] [Related]
19. Migration and activation of T cells during development of graft-versus-host disease in a mouse model.
Wen HS; Wang JM; Zhou H; Gong SI; Gao L; Wu Y
Transplant Proc; 2013 Mar; 45(2):713-8. PubMed ID: 23498811
[TBL] [Abstract][Full Text] [Related]
20. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
